Evofem Biosciences, Inc.
No enriched coverage for $EVFM in the last 7 days.
No SEC Form 4 filings for $EVFM in the last 30 days.
Evofem Biosciences, Inc. (EVFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THIS NOTE MAY NOT BE OFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHER
HUB Cyber Security (Nasdaq: HUBC) said it acquired senior subordinated convertible notes and purchase rights of Evofem Biosciences (OTCMKTS: EVFM) using only HUB equity, at no cash cost. HUB cited a broader restructuring to cut costs, reduce headcount ~50%, and improve liquidity/governance. Evofem reported $20M+ sales in 2025.
Recent EVFM coverage spans corporate actions and mergers & acquisitions.
The filing discloses a new, short-dated financing obligation that increases near-term cash outflow risk and may pressure liquidity.
The transaction could provide liquidity/exit for certain noteholders, but EVFM’s own equity holders’ payoff depends on conversion mechanics and deal terms not provided.
alphai scores every news story that mentions EVFM with an AI model for sentiment and relevance, and aggregates insider trades from Evofem Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Evofem Biosciences, Inc. (EVFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THIS NOTE MAY NOT BE OFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHER
2 min readHUB Cyber Security (Nasdaq: HUBC) said it acquired senior subordinated convertible notes and purchase rights of Evofem Biosciences (OTCMKTS: EVFM) using only HUB equity, at no cash cost. HUB cited a broader restructuring to cut costs, reduce headcount ~50%, and improve liquidity/governance. Evofem reported $20M+ sales in 2025.
4 min read
